Positive and Negative Predictive Value of a Non-Endoscopic Molecular Barrett’s Esophagus Detection Test in Screening Eligible Adults: Results from a Large Multicenter Population Based Clinical Trial ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based ...
Sending a text message reminder to participants about their upcoming fecal immunochemical test improved previously poor adherence rates for colorectal cancer screening. Participants who received a ...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present modeling data evaluating the ...
Multi-target stool DNA test adherence among average-risk 45- to 49-year-old patients from 2017-2023.
Adherence to multi-target stool DNA test in the US Asian population from 2017-2024. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not ...
Studies show higher completion rates for mt-sDNA testing and the positive impact of patient navigation in expanding access to underserved and older populations “Exact Sciences’ research at ACG 2025 ...
Trends in utilization of colorectal cancer screening modalities among patients with average risk in the United States from 2017 to 2023. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Mailing mt-sDNA tests to Medicare Advantage enrollees improved CRC screening adherence, with a 49.4% overall adherence rate. Digital outreach, especially combining email and text, significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results